Scholarlink

Background <p>There is limited data available on the efficacy and safety of Transscleral Lutein Iontophoresis (TSLI) in patients with intermediate age-related macular degeneration (iAMD) and reticular pseudodrusen (RPD).</p> Methods <p>This retrospective multicentre study evaluated the functional and morphological outcomes of TSLI in patients with stage 2 and stage 3 iAMD with RPD. Autofluorescence (AF), Optical Coherence Tomography (OCT), Best Corrected Visual Acuity (BCVA), Intraocular Pressure (IOP), Macular Sensitivity (MS) and adverse events, were recorded at baseline, 1 month and 3 months follow-up after treatment.</p> Results <p>Thirty eyes from 30 patients, (15 ♂: 15 ♀), mean age (70.3 ± 7.8 years) were included. BCVA improved significantly, from mean baseline 65.6 ± 8.6 ETDRS letters to 66.9 ± 8.0 at 1 month and 69.1 ± 7.8 at 3 months (ANOVA, <i>p</i> &lt; 0.0001, respectively), along with MS, (ANOVA <i>p</i> &lt; 0.001). There was a significant increase of stage 1 RPD (<i>p</i> = 0.002) and a decrease in stage 3 RPD (<i>p</i> = 0.020). The Outer Nuclear Layer (ONL) thickness increased significantly (ANOVA, <i>p</i> &lt; 0.0001). No adverse events were recorded.</p> Conclusion <p>TSLI appears to be an effective, safe technique in patients with iAMD and RPD, leading to structural and functional improvements in short-term follow-up.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Short-term efficacy and safety of transcleral lutein iontophoresis in patients with intermediate amd and reticular pseudodrusen: A retrospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月24日

查看全文
  • Mutasem Elfalah,
  • Enrico Borelli,
  • Paola Marolo,
  • Michele Reibaldi,
  • Vincenco De Angelis,
  • Carlo De Rosa,
  • Francesco Iatì,
  • Niccolò Castellino,
  • Sandrine Anne Zweifel,
  • Yacoub A. Yousef,
  • Daniela Bacherini,
  • Andrea Lucisano,
  • Adriano Carnevali,
  • Robert Rejdak,
  • Giuseppe Giannaccare,
  • Vincenzo Scorcia,
  • Mario Damiano Toro

摘要

Background

There is limited data available on the efficacy and safety of Transscleral Lutein Iontophoresis (TSLI) in patients with intermediate age-related macular degeneration (iAMD) and reticular pseudodrusen (RPD).

Methods

This retrospective multicentre study evaluated the functional and morphological outcomes of TSLI in patients with stage 2 and stage 3 iAMD with RPD. Autofluorescence (AF), Optical Coherence Tomography (OCT), Best Corrected Visual Acuity (BCVA), Intraocular Pressure (IOP), Macular Sensitivity (MS) and adverse events, were recorded at baseline, 1 month and 3 months follow-up after treatment.

Results

Thirty eyes from 30 patients, (15 ♂: 15 ♀), mean age (70.3 ± 7.8 years) were included. BCVA improved significantly, from mean baseline 65.6 ± 8.6 ETDRS letters to 66.9 ± 8.0 at 1 month and 69.1 ± 7.8 at 3 months (ANOVA, p < 0.0001, respectively), along with MS, (ANOVA p < 0.001). There was a significant increase of stage 1 RPD (p = 0.002) and a decrease in stage 3 RPD (p = 0.020). The Outer Nuclear Layer (ONL) thickness increased significantly (ANOVA, p < 0.0001). No adverse events were recorded.

Conclusion

TSLI appears to be an effective, safe technique in patients with iAMD and RPD, leading to structural and functional improvements in short-term follow-up.